Tag: Cellectis
Cellectis presents new editing processes by TALEN
By Claude Leguilloux Published on 04/23/2024 at 7:49 a.m. Photo credit © Cellectis – Ramon Martinez (Boursier.com)…
Cellectis: new approach to treating congenital metabolic diseases using modified stem cells
A.S. Published on 04/11/2024 at 2:16 p.m. Photo credit © Cellectis – Ramon Martinez (Boursier.com)…
Cellectis: fundraising on the menu for the next AGM
By Alexandra Saintpierre Published on 11/18/2023 at 5:16 p.m. (Boursier.com) — The biotechnology company Cellectis will hold its…
Cellectis: Signature of the definitive agreement with AstraZeneca
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
AstraZeneca invests in Cellectis – 01/11/2023 at 08:58
(AOF) – Cellectis has entered into a research collaboration agreement with AstraZeneca, an investment agreement for an initial investment of $80 million and a memorandum of understanding for a possible…
Cellectis: the title soars, alliance with AstraZeneca – 01/11/2023 at 09:49
(CercleFinance.com) – Cellectis soars on the Paris Stock Exchange on Wednesday after unveiling a strategic collaboration with the pharmaceutical giant AstraZeneca, which will allow the latter to take a 22%…
Immunology and oncology: AstraZeneca signs an agreement with the French Cellectis – 01/11/2023 at 11:24
The British pharmaceutical giant AstraZeneca announced on Wednesday “a collaboration and investment agreement with Cellectis”, a French biotechnology company, which should enable the development of new products “in immunology, oncology…
Cellectis: proof of concept of a gene surgery product candidate
AB Published on 10/13/2023 at 8:14 a.m. Photo credit © Cellectis – Ramon Martinez (Boursier.com) —…
Cellectis: the promises of gene editing for APDS1
(CercleFinance.com) – Cellectisa today announced the publication of an article in Molecular Therapy – Methods & Clinical Development, demonstrating the effectiveness of its TALEN® genome editing platform in editing the…
Cellectis: the promises of gene editing for APDS1 – 10/13/2023 at 10:18
(CercleFinance.com) – Cellectisa today announced the publication of an article in Molecular Therapy – Methods & Clinical Development, demonstrating the effectiveness of its TALEN® genome editing platform in editing the…
Cellectis: Half-year loss reduced, the stock goes up
Read also (CercleFinance.com) – Cellectis shares are sailing against the tide of the Parisian market on Tuesday morning following the publication of half-year results marked by a reduction in losses…
Cellectis reduces its losses in the second quarter of 2023
(AOF) – Cellectis reduced its losses in the second quarter of 2023 to 13.5 million dollars against 19.4 million dollars a year ago. Its operating loss over this period also…